drugset / Trial / NCT04147533
Efficacy and Safety of TKIs' Withdrawal After a Two-step Dose Reduction in Patients with Chronic Myeloid Leukemia
NaSingle-groupOpen-labelOther
Summary
Evaluation of the efficacy and safety of withdrawal of tyrosine kinase inhibitors after previous two-step dose reduction in patients with chronic myeloid leukemia in deep molecular remission
Timeline
- Start
- 2020-06-16
- Primary completion
- 2026-06
- Completion
- 2026-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Imatinib | Small molecule | 200 mg | — |
| Subject | Nilotinib | Small molecule | 400 mg | — |
| Subject | dasatinib anhydrous | Small molecule | 40 mg | — |